Chutes & Ladders: Merck realigns division chiefs; focuses on vaccines

Merck has realigned the positions of some of its top division chiefs as it focuses on several areas, especially the development of vaccines. Margaret McGlynn is being hustled into the president's spot of Merck Vaccines as the drug giant spurs the development of four late-stage vaccines. CFO Judy Lewent will also take on additional responsibilities in strategic planning.

- read this report from Newsday for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.